secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCA Healthcare, Inc. (HCA)
CIK:        0000860730
Form:       8-K
Filed at:   2021-10-27T23:59:59+00:00
Accession:  0001193125-21-309426
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCA Healthcare EVP & Chief Clinical Officer appointment; Dr. Perlin to depart March 2022
--------------------------------------------------------------------------------

- Dr. Jonathan B. Perlin will depart as President-Clinical Ops and CMO to become CEO of The Joint Commission, effective March 1, 2022.
- Dr. Perlin remains in current role through Dec 31, 2021; transition period from Jan 1 to Feb 28, 2022.
- Effective Jan 1, 2022, Dr. Michael S. Cuffe named Executive Vice President and Chief Clinical Officer.
- Board approved the changes at October 21, 2021 meeting; orderly succession for a key clinical leadership role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/860730/000119312521309426/0001193125-21-309426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/860730/000119312521309426/d222794d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-309426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer